A proof-of-concept study reported CRISPR base editors correcting Artemis mutations outside the body as a potential route for ART-SCID (Artemis-deficient severe combined immunodeficiency). The work focuses on editing the Artemis gene in a way that supports restoration of functional immune cell development. Separately, FDA communications also pointed toward operational efforts that could shorten DNA-to-IND timelines through better coordination between sponsors and qualifying research entities. Together, the items show both the scientific and process layers of gene therapy development maturing—improving editing feasibility while simultaneously optimizing how quickly candidates can reach first-in-human testing.